甲基苯丙胺相关肺动脉高压综述
本综述聚焦甲基苯丙胺相关肺动脉高压(MA-PAH),梳理其流行病学、病理生理、临床表现、诊断难点与管理策略。MA-PAH 在功能分级和血流动力学上较特发性肺动脉高压更严重,管理需整合肺血管扩张剂、戒断甲基苯丙胺及社会康复项目。
要点
- MA-PAH 功能分级与血流动力学较特发性肺动脉高压更严重。
- 发病机制涉及血清素信号改变、羧酸酯酶1活性降低、氧化应激及肺血管舒缩因子失调。
- 管理需肺血管扩张剂、戒断甲基苯丙胺及社会康复项目多管齐下。
核心结论
- 全球甲基苯丙胺使用激增与MA-PAH强相关,可能使MA-PAH发病率上升,构成紧迫的公共卫生挑战。
研究设计与样本
- 本文为综述,系统探讨MA-PAH的流行病学、病理生理、临床表现、诊断与管理策略。
主要发现
- MA-PAH发病机制尚未完全阐明,涉及血清素信号改变、羧酸酯酶1活性降低、氧化应激及肺血管舒缩因子失调,最终导致肺血管结构重塑。
- 与特发性肺动脉高压相比,MA-PAH在功能分级和血流动力学方面表现更严重。
临床怎么用
- MA-PAH管理采用多层面方法,整合肺血管扩张剂、戒断甲基苯丙胺及社会与康复项目,以改善结局并检测潜在复发以及时干预。
局限性
- MA-PAH发病机制尚未完全描述,综述指出知识空白以指导未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC IMPORTANCE: The global surge in methamphetamine use is a critical public health concern, particularly due to its robust correlation with methamphetamine-associated pulmonary arterial hypertension (MA-PAH). This association raises urgent alarms about the potential escalation of MA-PAH incidence, posing a significant and imminent challenge to global public health. REVIEW FINDINGS: This comprehensive review meticulously explores MA-PAH, offering insights into its epidemiology, pathophysiology, clinical presentation, diagnostic intricacies, and management strategies. The pathogenesis, yet to be fully described, involves complex molecular interactions, including alterations in serotonin signaling, reduced activity of carboxylesterase 1, oxidative stress, and dysregulation of pulmonary vasoconstrictors and vasodilators. These processes culminate in the structural remodeling of the pulmonary vasculature, resulting in pulmonary arterial hypertension. MA-PAH exhibits a more severe clinical profile in functional class and hemodynamics compared with idiopathic pulmonary arterial hypertension. Management involves a multifaceted approach, integrating pulmonary vasodilators, cessation of methamphetamine use, and implementing social and rehabilitation programs. These measures aim to enhance patient outcomes and detect potential relapses for timely intervention. SUMMARY: This review consolidates our understanding of MA-PAH, pinpointing knowledge gaps for future studies. Addressing these gaps is crucial for advancing diagnostic accuracy, unraveling mechanisms, and optimizing treatment for MA-PAH, thereby addressing the evolving landscape of this complex health concern.
引用
- Charoenpong P, Hall NM, Keller CM, et al. Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension. Chest. 2024. PMID: 38211700. doi:10.1016/j.chest.2024.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。